All-oral Hep C race heats up as AbbVie receives "breakthrough" status

Share this article:

AbbVie joined BMS today in gaining Breakthrough Therapy designation for an investigational Hep C treatment. The three drug combo of ABT-450/r (protease inhibitor and ritonavir), ABT-267 (an NS5A inhibitor) and ABT-333 (a non-nucleoside polymerase inhibitor) treats patients with genotype 1 of the chronic disease.

FDA's Breakthrough Therapy nod follows a promising Phase II clinical trial, named ‘Aviator'. In that trial, the three-drug combo saw 99% of patients hit the key benchmark of sustained viral response after 12 weeks of therapy. The combo will now move to Phase III trials.

John Leonard, SVP and Chief Scientific Officer, AbbVie, said in a release: "AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. We feel it reflects the potential of this regimen to be important in the treatment of HCV."

Five days ago, Gilead released data from its Phase II "Lonestar" study, in which the company tested a combination of sofosbuvir, which has been submitted for FDA approval, and ledipasvir. The Foster-City, California based drugmaker said the virus was undetectable in 19 out of 20 subjects after only eight weeks.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.